Tigermed Releases Its 2019 Half-yearly Report, with Year On Year Net Profit Up 61.03%
August 29, 2019
Tigermed (Chinese Stock code: 300347), a company that aims to provide full services for clinical research which enable companies in the pharmaceutical, biotech and medical device industries worldwide to market their innovative medical products, as well as deliver pioneering treatments to patients, announces its financial results for the six months ended August. 22nd, 2019.
According to the report, Tigermed’s revenue and net profit continue to grow rapidly in the first half of 2019.
The total revenue reached about RMB1.3 billion(equals to USD9.1 billion), up 29.49% year on year, and the net profit attributable to the owners of the company reached RMB 352 million, up 61.04% year on year.
As for the main business, the clinical trial technical service earns more than RMB 634 million, with a growth of 26.65% than the same period of last year; the clinical trial consulting service creates an income of RMB 697 million, with a growth of 31.15% than the same period of last year.
In addition, basic earnings per share increased from RMB 0.44 to 0.71, up 61.37% accordingly.
Hangzhou Tigermed Consulting Co., Ltd（stock symbol: 300347） is a leading Contract Research Organization (CRO) in China dedicated to provide professional full clinical trial services. Since inception in 2004, Tigermed has been committed to accelerating medical product development with costs efficiency and quality. Headquartered in Hangzhou, Tigermed operates 32 subsidiaries, 95 offices across China and 12 overseas offices in Hong Kong China, Taiwan China, USA, Switzerland, Korea, Australia, Japan, Malaysia, Singapore , India and Romania with over 4100 full time staffs. Tigermed has serviced more than 600 local and global clients in the conduct of over 1060 clinical trials. Tigermed is recognized as “The Innovative CRO” in China，owning to our involvement of over 150 innovative drugs.